The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Arbaclofen in fragile X syndrome: results of phase 3 trials
Open accessAbstract
Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for social avoidance in FXS. Two phase 3 placebo-controlled trials were conducted, a flexible dose trial in subjects age 12–50 (209FX301, adolescent/adult study) and a fixed dose trial in subjects age 5–11 (209FX302, child study). The primary endpoint for both trials was the Social Avoidance subscale of the Aberrant Behavior Checklist-Community Edition, FXS-specific (ABC-C FX ). Secondary outcomes included other ABC-C FX subscale scores, Clinical Global Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), and Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Socialization domain score. A total 119 of 125 randomized subjects completed the adolescent/adult study ( n = 57 arbaclofen, 62 placebo) and 159/172 completed the child study (arbaclofen 5 BID n = 38; 10 BID n = 39; 10 TID n = 38; placebo n = 44). There were no serious adverse events (AEs); the most common AEs included somatic (headache, vomiting, nausea), neurobehavioral (irritability/agitation, anxiety, hyperactivity), decreased appetite, and infectious conditions, many of which were also common on placebo. In the combined studies, there were 13 discontinuations ( n = 12 arbaclofen, 1 placebo) due to AEs (all neurobehavioral). The adolescent/adult study did not show benefit for arbaclofen over placebo for any measure. In the child study, the highest dose group showed benefit over placebo on the ABC-C FX Irritability subscale ( p = 0.03) and Parenting Stress Index (PSI, p = 0.03) and trends toward benefit on the ABC-C FX Social Avoidance and Hyperactivity subscales (both p < 0.1) and CGI-I ( p = 0.119). Effect size in the highest dose group was similar to effect sizes for FDA-approved serotonin reuptake inhibitors (SSRIs). Arbaclofen did not meet the primary outcome of improved social avoidance in FXS in either study. Data from secondary measures in the child study suggests younger patients may derive benefit, but additional studies with a larger cohort on higher doses would be required to confirm this finding. The reported studies illustrate the challenges but represent a significant step forward in translating targeted treatments from preclinical models to clinical trials in humans with FXS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase III study, children receiving the highest dose of arbaclofen also showed improvement over placebo on the secondary end points of the ABC-CFX Irritability subscale (P = 0.03) and the Parenting Stress Index (P = 0.03).”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [72]
In the citing paper
“In the phase III study carried out in children, the primary end point (ABC-CFX Social Avoidance subscale) narrowly missed significant improvement (P = 0.08)72.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [72]
In the citing paper
“This trial was limited by a lack of full enrolment due to financial issues for the sponsor, the use of fixed rather than flexible dosing and possible inflation of symptoms by families in order to meet inclusion criteria72.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [72]
In the citing paper
“However, the adult studies of FXS did not demonstrate efficacy and the pediatric trials did not reach significance for the primary outcome measure, but did show limited improvements in secondary measures including the Parenting Stress Index because of lowered irritability in the children [132].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [132]
In the citing paper
“However, the adult studies of FXS did not demonstrate efficacy and the pediatric trials did not reach significance for the primary outcome measure, but did show limited improvements in secondary measures including the Parenting Stress Index because of lowered irritability in the children [132].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [132]
In the citing paper
“However, the adult studies of FXS did not demonstrate efficacy and the pediatric trials did not reach significance for the primary outcome measure, but did show limited improvements in secondary measures including the Parenting Stress Index because of lowered irritability in the children [132].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [132]
In the citing paper
“The promising mouse studies led to human trials in FXS [131] that initially showed improvements in those with ASD plus FXS leading to phase 3 trials in FXS [132].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Owens, J. A., Spirito, A., & McGuinn, M. (2000) · Sleep · doi:10.1093/sleep/23.8.1d · Cited by 2,535
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Size of Treatment Effects and Their Importance to Clinical Research and Practice
KRAEMER, H. C., & Kupfer, D. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.014 · Cited by 850
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J., & Mandel, J. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 781
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Self-citationEpidemiology of fragile X syndrome: A systematic review and meta‐analysis
Hunter, J. E., Rivero‐Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36511 · Cited by 464
Psychometric characteristics of the aberrant behavior checklist.
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985) · PubMed · Cited by 458
Autism Profiles of Males With Fragile X Syndrome
Harris, S. W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barbato, I., Tassone, F., Hagerman, P. J., Herman, K., & Hagerman, R. J. (2008) · American Journal on Mental Retardation · doi:10.1352/2008.113:427-438 · Cited by 396
Self-citation
Research works printed but not linked: 7
- Qin M, Huang T, Kader M, Krych L, Xia Z, Burlin T, Zeidler Z, Zhao T, Smith CB. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome. Int J Neuropsychopharmacol. 2015;18(9). · DOI · Paper page
- Sparrow S, Cicchetti D, Balla D. Vineland adaptive behavior scales, second edition (Vineland II). Survey interview form/caregiver rating form. Livonia: Pearson Assessments; 2005.
- Kaufmann WE, Walton-Bowen K, Kuriyama N, Cherubini M, Carpenter RL, Bear MF PW. Randomized, controlled, phase 2 trial of STX209 (arbaclofen) for social function in autism spectrum disorder. Ann Neurol (Suppl). 2013;74:S130.
- Snape M, Horrigan J, Glass L, Berry-Kravis E, Hatti S, Visootsak J, Frazier J, Tranfaglia M, Jones N. Development of the fragile X syndrome rating scale. In: IMFAR. 2014.
- Sansone SM, Berry-Kravis E, Crestodina C, McLennan Y, Hagerman R, Hessl D. Sensitivity of an eye tracking paradigm as an outcome measure in a fragile X syndrome targeted treatment clinical trial. In: 49th Annual Gatlinburg conference on research and theory in intellectual and developmental disabilities; San Diego. 2016.
- De Sonia A, Visootsak J, Smith M, Budimirovic D, Tartaglia N, Welnik N, et al. Analysis of arbaclofen responses in fragile X syndrome. In: 14th International Fragile X Conference; Orange County, CA. 2014.
- Berry-Kravis E, Erickson CA, Kolevzon A, N T, Hagerman R, Hatti S, Frazier J, Sanders K, Challman T, Needelman H, et al: The treatment of fragile X syndrome with Trofinetide (NNZ-2566). In Proceedings of the 15th international fragile X conference; San Antonio. 2016
Cited by
Sorted by citations
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationDrug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationAn Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
Self-citationAn update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
An update on pharmacotherapy of autism spectrum disorder in children and adolescents
Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1458706 · Cited by 194
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry‐Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D. R., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 159
Self-citationHessl, D., Sansone, S. M., Berry-Kravis, E., Riley, K., Widaman, K. F., Abbeduto, L., Schneider, A., Coleman, J., Oaklander, D., Rhodes, K. C., et al. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9167-4 · Cited by 126
Self-citationBerry-Kravis, E. M., Harnett, M. D., Reines, S. A., Reese, M. A., Ethridge, L. E., Outterson, A. H., Michalak, C., Furman, J., & Gurney, M. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01321-w · Cited by 131
Self-citationGreen, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 138
Greiss Hess, L., Fitzpatrick, S. E., Nguyen, D. V., Chen, Y., Gaul, K. N., Schneider, A., Lemons Chitwood, K., Eldeeb, M. A. A. A., Polussa, J., Hessl, D., et al. (2016) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000334 · Cited by 122
Self-citationHeussler, H., Cohen, J., Silove, N., Tich, N., Bonn-Miller, M. O., Du, W., O’Neill, C., & Sebree, T. (2019) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9277-x · Cited by 106
Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder
Banerjee, A., Miller, M. T., Li, K., Sur, M., & Kaufmann, W. E. (2018) · Brain · doi:10.1093/brain/awy323 · Cited by 115
Self-citationTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Self-citationStoppel, L. J., Kazdoba, T. M., Schaffler, M. D., Preza, A. R., Heynen, A., Crawley, J. N., & Bear, M. F. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.236 · Cited by 92
Self-citationFragile X Syndrome: From Molecular Aspect to Clinical Treatment
Protic, D. D., Aishworiya, R., Salcedo‐Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041935 · Cited by 103
Self-citationPlacebo‐controlled crossover assessment of mecasermin for the treatment of Rett syndrome
O’Leary, H. M., Kaufmann, W. E., Barnes, K. V., Rakesh, K., Kapur, K., Tarquinio, D. C., Cantwell, N. G., Roche, K. J., Rose, S. A., Walco, A. C., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.533 · Cited by 83
Self-citationLopatina, O. L., Malinovskaya, N. A., Komleva, Y. K., Gorina, Y. V., Shuvaev, A. N., Olovyannikova, R. Y., Belozor, O. S., Belova, O. A., Higashida, H., & Salmina, A. B. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0014 · Cited by 74
Budimirovic, D. B., Schlageter, A. M., Filipovic-Sadic, S., Protic, D. D., Bram, E. E., Mahone, E. M., Nicholson, K., Culp, K., Javanmardi, K., Kemppainen, J., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10100694 · Cited by 79
Self-citationBonnycastle, K., Davenport, E. C., & Cousin, M. A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15035 · Cited by 78
Asiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78
Self-citationGABAergic Inhibition Gates Perceptual Awareness During Binocular Rivalry
Mentch, J., Spiegel, A. C., Ricciardi, C., & Robertson, C. E. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0836-19.2019 · Cited by 79
The virtuous cycle of human genetics and mouse models in drug discovery
Nadeau, J. H., & Auwerx, J. H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0009-9 · Cited by 78
Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 73
Self-citationNeural circuits regulating prosocial behaviors
Walsh, J. J., Christoffel, D. J., & Malenka, R. C. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01348-8 · Cited by 72
Farmer, C., Swineford, L., Swedo, S. E., & Thurm, A. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9222-9 · Cited by 69
Metformin treatment in young children with fragile X syndrome
Biag, H. M. B., Potter, L. A., Wilkins, V., Afzal, S., Rosvall, A., Salcedo‐Arellano, M. J., Rajaratnam, A., Manzano‐Nunez, R., Schneider, A., Tassone, F., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.956 · Cited by 68
Self-citationFragile X syndrome and fragile X-associated tremor ataxia syndrome
Hall, D. A., & Berry‐Kravis, E. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00025-7 · Cited by 65
Self-citationRevisiting the excitation/inhibition imbalance hypothesis of ASD through a clinical lens
Port, R. G., Oberman, L. M., & Roberts, T. P. L. (2019) · British Journal of Radiology · doi:10.1259/bjr.20180944 · Cited by 68
Targeted Reactivation of FMR1 Transcription in Fragile X Syndrome Embryonic Stem Cells
Haenfler, J. M., Skariah, G., Rodriguez, C. M., da Rocha, A. M., Parent, J. M., Smith, G. D., & Todd, P. K. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00282 · Cited by 59
Precision Medicine Care in ADHD: The Case for Neural Excitation and Inhibition
Mamiya, P. C., Arnett, A. B., & Stein, M. A. (2021) · Brain Sciences · doi:10.3390/brainsci11010091 · Cited by 67
Díaz‐Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marín, Ó., Bagni, C., Umbricht, D., Simonoff, E. A., Andres-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 56
Self-citationLamy, M., & Erickson, C. A. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2018.08.015 · Cited by 60
Berg, A. T., Palac, H., Wilkening, G. N., Zelko, F. A. J., & Schust, L. F. (2020) · Epilepsia · doi:10.1111/epi.16750 · Cited by 59
Neurobiology of ARID1B haploinsufficiency related to neurodevelopmental and psychiatric disorders
Moffat, J. J., Smith, A. L., Jung, E., Ka, M., & Kim, W.-Y. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01060-x · Cited by 53
Berg, A. T., Gaebler-Spira, D. J., Wilkening, G. N., Zelko, F. A. J., Knupp, K. G., Dixon‐Salazar, T., Villas, N., Meskis, M. A., Harwell, V., Thompson, T., et al. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107287 · Cited by 55
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
Fragile X syndrome and fragile X-associated disorders
Rajaratnam, A., Shergill, J., Salcedo‐Arellano, M. J., Saldarriaga, W., Duan, X., & Hagerman, R. J. (2017) · F1000Research · doi:10.12688/f1000research.11885.1 · Cited by 53
Self-citationInterneuron Dysfunction and Inhibitory Deficits in Autism and Fragile X Syndrome
Nomura, T. (2021) · Cells · doi:10.3390/cells10102610 · Cited by 51
Bennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Huang, Q., Pereira, A. C., Velthuis, H., Wong, N. M. L., Ellis, C. L., Ponteduro, F. M., Dimitrov, M., Kowalewski, Ł., Lythgoe, D. J., Rotaru, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg7859 · Cited by 48
Novel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 51
Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future
van Karnebeek, C., Bowden, K., & Berry‐Kravis, E. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.07.010 · Cited by 43
Self-citationGABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators
Nieto, A., Bailey, T., Kaczanowska, K., & McDonald, P. H. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_232 · Cited by 43
Keeping the Balance: GABAB Receptors in the Developing Brain and Beyond
Bassetti, D. (2022) · Brain Sciences · doi:10.3390/brainsci12040419 · Cited by 47
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
Luu, S., Province, H. S., Berry‐Kravis, E., Hagerman, R. J., Hessl, D. R., Vaidya, D. M., Lozano, R., Rosselot, H., Erickson, C. A., Kaufmann, W. E., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10090629 · Cited by 41
Self-citationRepurposing available drugs for neurodevelopmental disorders: The fragile X experience
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R. J., Guilliams, T., & Cogram, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 41
Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome
Morin‐Parent, F., Champigny, C. M., Lacroix, A., Corbin, F., & Lepage, J. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0650-z · Cited by 46
Bertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T. J., Keller, R., Bianco, A., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_16 · Cited by 43
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38
Self-citationLamy, M., Pedapati, E. V., Dominick, K. C., Wink, L. K., & Erickson, C. A. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00408-0 · Cited by 39
EEG as a translational biomarker and outcome measure in fragile X syndrome
Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 36
Molecular Biomarkers in Fragile X Syndrome
Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 36
Dysregulated Prefrontal Cortex Inhibition in Prepubescent and Adolescent Fragile X Mouse Model
Kramvis, I., van Westen, R., Lammertse, H. C. A., Riga, D., Heistek, T. S., Loebel, A., Spijker, S., Mansvelder, H. D., & Meredith, R. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00088 · Cited by 34
Arnett, A. B., Wang, T., Eichler, E. E., & Bernier, R. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09371-4 · Cited by 33
Möhrle, D., Wang, W., Whitehead, S. N., & Schmid, S. (2021) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2021.710593 · Cited by 32
Auditory hypersensitivity and processing deficits in a rat model of fragile X syndrome
Auerbach, B. D., Manohar, S., Radziwon, K. E., & Salvi, R. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105541 · Cited by 34
Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial
Mahdavinasab, S.-M., Saghazadeh, A., Motamed-Gorji, N., Vaseghi, S., Mohammadi, M.-R., Alikhani, R., & Akhondzadeh, S. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-019-01333-5 · Cited by 32
Salcedo‐Arellano, M. J., Cabal-Herrera, A. M., Punatar, R., Clark, C. J., Romney, C. A., & Hagerman, R. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00968-6 · Cited by 32
Self-citationDecades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Henneberry, E. A., Lamy, M., Dominick, K. C., & Erickson, C. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05237-9 · Cited by 32
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Hong, D., & Iakoucheva, L. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02356-y · Cited by 32
Modelling fragile X syndrome in the laboratory setting: A behavioral perspective
Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 31
Bird, L. M., Ochoa‐Lubinoff, C., Tan, W., Heimer, G., Melmed, R. D., Rakhit, A., Visootsak, J., During, M. J., Holcroft, C., Burdine, R. D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011409 · Cited by 28
Self-citationGABAergic abnormalities in the fragile X syndrome.
Van der Aa, N., & Kooy, R. F. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.12.022 · Cited by 26
Emerging pharmacological therapies in fragile X syndrome and autism
Yamasue, H., Aran, A. A., & Berry‐Kravis, E. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000703 · Cited by 26
Self-citationDhaliwal, N. K., Weng, O. Y., Dong, X., Bhattacharya, A., Ahmed, M. E., Nishimura, H., Choi, W. W. Y., Aggarwal, A., Luikart, B. W., Shu, Q., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114173 · Cited by 27
Hessl, D. R., Harvey, D. J., Sansone, S. M., Crestodina, C., Chin, J. A., Joshi, R., Hagerman, R. J., & Berry‐Kravis, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209984 · Cited by 26
Self-citationPhotocontrol of Endogenous Glycine Receptors In Vivo
Gomila, A. M. J., Rustler, K., Maleeva, G., Nin‐Hill, A., Wutz, D., Bautista-Barrufet, A., Rovira, X., Bosch, M., Mukhametova, E., Petukhova, E. O., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.08.005 · Cited by 23
Jiang, S., Xiao, L., Sun, Y., He, M., Gao, C., Zhu, C., Chang, H., Ding, J., Li, W., Wang, Y., et al. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12670 · Cited by 23
Dysregulated translational control in brain disorders: from genes to behavior
Wiebe, S. A., Nagpal, A., & Sonenberg, N. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.005 · Cited by 24
Molosh, A. I., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.014 · Cited by 24
An “Omic” Overview of Fragile X Syndrome
Dionne, O., & Corbin, F. (2021) · Biology · doi:10.3390/biology10050433 · Cited by 24
Fragile X syndrome clinical trials: exploring parental decision‐making
D'Amanda, C. S., Peay, H. L., Wheeler, A., Turbitt, E., & Biesecker, B. B. (2019) · Journal of Intellectual Disability Research · doi:10.1111/jir.12605 · Cited by 21
Sato, A., & Ikeda, K. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.08.005 · Cited by 22
Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
Budimirovic, D. B., Dominick, K. C., Gabis, L. V., Adams, M., Adera, M., Huang, L., Ventola, P. E., Tartaglia, N. R., & Berry‐Kravis, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757825 · Cited by 21
Self-citationZeidler, S., de Boer, H., Hukema, R. K., & Willemsen, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00368 · Cited by 23
Sudhahar, S., Özer, B., Chang, J., Chadwick, W., O’Donovan, D., Campbell, A., Tulip, E., Thompson, N. T., & Roberts, I. (2024) · Nature Communications · doi:10.1038/s41467-024-50024-6 · Cited by 21
Deciphering the physiopathology of neurodevelopmental disorders using brain organoids
Dionne, O., Sabatié, S., & Laurent, B. (2024) · Brain · doi:10.1093/brain/awae281 · Cited by 22
mTOR-Dependent Spine Dynamics in Autism
Chaudry, S., & Vasudevan, N. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.877609 · Cited by 23
Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments
Verdura, E., Pérez‐Cano, L., Sabido-Vera, R., Güney, E., Hyvelin, J.-M., Durham, L. A., & Gomez‐Mancilla, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.722378 · Cited by 19
Leone, R., Zuglian, C., Brambilla, R., & Morella, I. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407865 · Cited by 22
Pandina, G., Ring, R. H., Bangerter, A., & Ness, S. L. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.08.003 · Cited by 19
Berry‐Kravis, E. (2022) · Journal of Child Neurology · doi:10.1177/08830738221089740 · Cited by 19
Self-citationBrašić, J. R., Nandi, A., Russell, D., Jennings, D. L., Barret, O., Mathur, A., Slifer, K. J., Sedlak, T. W., Martin, S., Brinson, Z. S., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10120899 · Cited by 18
Self-citationDerieux, C., Léauté, A., Brugoux, A., Jaccaz, D., Terrier, C., Pin, J., Kniazeff, J., Merrer, J. L., & Becker, J. A. J. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01317-1 · Cited by 16
Agmatine relieves behavioral impairments in Fragile X mice model
Jeon, S. J., Kwon, H., Bae, H. J., Gonzales, E. L., Kim, J.-H., Chung, H. J., Kim, D. H., Ryu, J. H., & Shin, C. Y. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109234 · Cited by 17
Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model
Zeidler, S., Pop, A. S., Jaafar, I. A., de Boer, H., Buijsen, R. A. M., de Esch, C. E. F., Nieuwenhuizen‐Bakker, I., Hukema, R. K., & Willemsen, R. (2018) · Brain and Behavior · doi:10.1002/brb3.991 · Cited by 17
Bruno, J. L., Hosseini, S. M. H., Lightbody, A. A., Manchanda, M. K., & Reiss, A. L. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858304 · Cited by 16
Jiang, S., He, M., Xiao, L., Sun, Y., Ding, J., Li, W., Guo, B., Wang, L., Wang, Y., Gao, C., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.835993 · Cited by 19
Neurodevelopment and early pharmacological interventions in Fragile X Syndrome
Milla, L. A., López‐Corral, L., Rivera, J., Zúñiga, N., Pino, G., Nunez-Parra, A., & Rio, C. A. C.-D. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1213410 · Cited by 15
New Therapeutic Options for Fragile X Syndrome
Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15
Pandina, G., Ring, R. H., Bangerter, A., & Ness, S. L. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.12.004 · Cited by 16
Bassetti, D., Lombardi, A., Kirischuk, S., & Luhmann, H. J. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa187 · Cited by 15
Reines, V., Charen, K. H., Rosser, T. C., Eisen, A., Sherman, S. L., & Visootsak, J. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0111-x · Cited by 15
Self-citationMüller, A. R., van Silfhout, N. Y., den Hollander, B., Kampman, D. H. C., Bakkum, L., Brands, M. M. M. G., Haverman, L., Terwee, C. B., Schuengel, C., Daams, J. G., et al. (2024) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040241245721 · Cited by 13
A novel eye‐tracking paradigm for indexing social avoidance‐related behavior in fragile X syndrome
Klusek, J., Moser, C., Schmidt, J., Abbeduto, L., & Roberts, J. E. (2019) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32757 · Cited by 15
Zeid, A. M., Nasr, J. J., Belal, F. F., Walash, M. I., Kaji, N., & Baba, Y. (2020) · Microchemical Journal · doi:10.1016/j.microc.2020.105770 · Cited by 13
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R. J., & Restrepo, B. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022006 · Cited by 16
Self-citationCordeiro, L., Braden, M. L., Coan, E., Welnick, N., Tanda, T., & Tartaglia, N. R. (2020) · Brain Sciences · doi:10.3390/brainsci10040248 · Cited by 16
Cordeiro, L., Villagomez, A. N., Swain, D. M., Deklotz, S., & Tartaglia, N. R. (2020) · Brain Sciences · doi:10.3390/brainsci10060351 · Cited by 12
Saraf, T. S., McGlynn, R. P., Bhatavdekar, O., Booth, R. G., & Canal, C. E. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00574 · Cited by 12
Metadata
- Authors
- Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., & Carpenter, R. L.
- Affiliations
- University of California Davis Medical Center (US)
- Emory University (US)
- Kennedy Krieger Institute (US)
- Boston Children's Hospital (US)
- Seaside Therapeutics (United States) (US)
- Simons Foundation (US)
- Autism Speaks (US)
- Massachusetts Institute of Technology (US)
- Rett Syndrome Research Trust (US)
- Venue
- Journal of Neurodevelopmental Disorders
- Published
- 2017-06-12
- Volume
- 9
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1866-1947 (ISSN-L)
- 1866-1955
- PMC
- PMC5467054
- OpenAlex
- W2576165191
- Cited by
- 183
- References
- 39
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 16 · 2023: 13 · 2022: 22 · 2021: 21 · 2020: 24 · 2019: 23 · 2018: 17 · 2017: 11
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Neurodevelopmental Disorders (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Seaside Therapeutics, Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- fragile X syndrome, social avoidance, irritability, hyperactivity, parental stress, adaptive behavior, adverse events, dose-response relationship, children and adolescents, serotonin reuptake inhibitors, NMDA receptor antagonists, behavioral phenotypes, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
